Green light for first treatment to target ovarian cancer with BRCA mutation The European Medicines Agency has recommended that Lynparza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options.…
First drug for rare sun disease recommended for approval in Europe The European Medicines Agency recommends that Scenesse (afamelanotide) should be approved for the prevention of severe sunburn in patients with erythropoietic protoporphyria.…
Valproate poses risk to unborn children, says European regulator Review recommends that valproate should not be prescribed to treat bipolar disorder or epilepsy in pregnant women or women or girls of childbearing age unless there is no alternative product.…
EMA expands public access to suspected drug side effect dataThe public now has access to a website containing reports of suspected side effects of drugs authorised by medicines safety regulators in European Union member states.…
European Medicines Agency reduces clinical trial secrecy The EMA has made a landmark policy move that will see it publish the clinical trial reports underpinning a medicine’s licence.…
Cancer drugs approved faster in the United States than in Europe or Canada Regulatory agencies in the United States take less time to approve new cancer drugs than those in Europe or Canada, according to new research.…
European Medicines Agency to review Ebola therapiesExperimental Ebola treatments are to be reviewed by the European Medicines Agency as part of the international response to the disease outbreak in West Africa.…
Patients to get a voice in European Medicines Agency pilot For the first time patients will be invited to give their views on the benefits and risks of some medicines in meetings with the European Medicines Agency’s Committee for Medicinal Products for Human Use.…
Clinical Pharmacist’s monthly news round-up: the top 10 in September 2014What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month……
OTC domperidone will be missedThe antiemetic domperidone’s reclassification shows the importance of pharmacovigilance, but the loss of such a useful over-the-counter medicine ought to have been better communicated to community pharmacies.…